Estradiol valerate/dienogest: In oral contraception

Drugs

Volumn 69, Issue 12, 2009, Pages 1635-1646

  Hoy, Sheridan M ^a,b   Scott, Lesley J ^a,b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b WOLTERS KLUWER HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BARBITURIC ACID DERIVATIVE; CARBAMAZEPINE; CIMETIDINE; DIENOGEST PLUS ESTRADIOL VALERATE; DILTIAZEM; ESTRADIOL VALERATE; ETHINYLESTRADIOL PLUS LEVONORGESTREL; FELBAMATE; GRISEOFULVIN; MACROLIDE; NEVIRAPINE; OXCARBAZEPINE; PHENYTOIN; PRIMIDONE; PYRROLE DERIVATIVE; QLAIRA; RIFAMPICIN; RITONAVIR; TOPIRAMATE; UNCLASSIFIED DRUG; VERAPAMIL;

ABDOMINAL PAIN; ACNE; ALOPECIA; AREA UNDER THE CURVE; BLEEDING DISORDER; BREAST CANCER; CLINICAL TRIAL; CYST RUPTURE; DEATH; DIARRHEA; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FIRST PASS EFFECT; HEADACHE; HUMAN; MASTALGIA; METRORRHAGIA; MIGRAINE; MULTIPLE CYCLE TREATMENT; ORAL CONTRACEPTION; OVULATION INHIBITION; PATIENT COMPLIANCE; PATIENT SATISFACTION; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SPOTTING; VAGINA CANDIDIASIS; WEIGHT GAIN; WITHDRAWAL BLEEDING;

ADOLESCENT; ADULT; CHEMISTRY, PHARMACEUTICAL; CONTRACEPTIVES, ORAL; DRUG COMBINATIONS; ESTRADIOL; FEMALE; HUMANS; MIDDLE AGED; NANDROLONE; PREGNANCY; YOUNG ADULT;

EID: 68949116444     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11202820-000000000-00000     Document Type: Review

References (19)

1. Moore C, Elger W, Graeser T, et al. Different alternatives for the substitution of ethinylestradiol in oral contraceptives. In: Kuhl H, Nikolov R, editors. Re-evaluation of contraceptive steroids. Bad Blankenburg: Harfe Verlag, 1998: 25-35
2. Endrikat J, Parke S, Trummer D, et al. Ovulation inhibition with four variations of a four-phasic estradiol valerate/dienogest combined oral contraceptive: results of two prospective, randomized, open-label studies. Contraception 2008 Sep; 78 (3): 218-25
3. Rowlands S. New technologies in contraception. BJOG 2009 Jan; 116 (2): 230-9
4. Wellington K, Perry CM. Estradiol valerate/dienogest. Drugs 2002; 62 (3): 491-504; discussion 505-6
5. Loose DS, Stancel G.M. Estrogens and progestins. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman & Gilman's the pharmacological basis of therapeutics. 11th ed. New York: McGraw-Hill, 2005: 1541-71
6. Oettel M, Carol W, Elger W, et al. A 19-norprogestin without 17α-ethinyl group II: dienogest from a pharmacodynamic point of view. Drugs Today 1995; 31 (7): 517-36
7. OetellM, Bervoas-Martin S, ElgerW, et al. A 19-norprogestin without a 17α-ethinyl group I: dienogest from a pharmacokinetic point of view. Drugs Today 1995; 31 (7): 499-516
8. Bayer plc. Qlaira summary of product characteristics [online]. Available from URL: http://emc.medicines.org.uk/medicine/21700/SPC/Qlaira/ [Accessed 2009 Jun 3]
9. Parke S, JungeW,Mellinger U, et al. Comparative effects of a four-phasic regimen of estradiol valerate/dienogest versus ethinylestradiol/levonorgestrel on haemostatic parameters [abstract no. O-193]. Hum Reprod 2008; 23 Suppl. 1: i78-9. Plus oral presentation from the 24th Annual Meeting of the European Society of Human Reproduction and Embryology; 2008 Jul 6-9; Barcelona
10. Parke S, Nahum GG, Mellinger U, et al. Metabolic effects of a new four-phasic oral contraceptive containing estradiol valerate and dienogest [abstract]. Obstet Gynecol 2008 Apr; 111 (Suppl. 4): 12-3S. Plus poster presentation from the American College of Obstetricians and Gynecologists 56th Annual Clinical Meeting; 2008 May 3-7; New Orleans (LA)
11. Zeun S, Lu M, Uddin A, et al. Pharmacokinetics of an oral contraceptive containing oestradiol valerate and dienogest. Eur J Contracept Reprod Health Care 2009 Jun; 14 (3): 221-32
12. Ahrendt H-J, Makalová D, Parke S, et al. Bleeding patterns and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized, comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel. Contraception. Epub 2009 May 14
13. Nahum GG, Parke S,Wildt L, et al. Efficacy and tolerability of a new oral contraceptive containing estradiol and dienogest [abstract]. Obstet Gynecol 2008 Apr; 111 Suppl. 4: 15S. Plus poster presentation from the American College of Obstetricians and Gynecologists 56th Annual Clinical Meeting; 2008 May 3-7; New Orleans (LA)
14. Nelson A, Sampson-Landers C, Parke S, et al. Efficacy of estradiol valerate/dienogest OC: results of 3 large studies in North America and Europe [abstract plus poster presentation]. The American College of Obstetricians and Gynecologists 57th Annual Clinical Meeting; 2009 May 2-6; Chicago (IL)
15. Hoogland HJ, Skouby SO. Ultrasound evaluation of ovarian activity under oral contraceptives. Contraception 1993 Jun; 47 (6): 583-90
16. Bayer Schering Pharma. Data on File. 2009
17. Bayer Schering Pharma. First estradiol-based oral contraceptiveQlaira ® cleared for market launch in Europe [online]. Available from URL: http://www.viva.vita.bayerhealthcare. com/index.php?id=36&tx-ttnews[tt-news] =12755&cHash=22c735fdf3 [Accessed 2009 Apr 24]
18. Bayer Schering Pharma. Bayer Schering Pharma paves the way to the next important oral contraceptive milestone [online]. Available from URL: http://www.viva.vita.bayerhealthcare.com/index.php?id=36&tx-ttnews[tt-news]= 12170 &cHash=c42fcdc686 [Accessed 2009 Apr 24]
19. Bayer Schering Pharma. Bayer submits first-in-class estradiol-based oral contraceptive for approval in the U.S. [online]. Available from URL: http://www.viva.vita.bayerhealthcare.com/index.php?id=36&no-cache= 1&tx-ttnews[tt-news]=13235 [Accessed 2009 Jul 9]